Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Gilead Sciences, Inc. (GILD). You can receive reports or configure the research engine for yourself.
Report On:
Gilead Sciences, Inc. (GILD)
HEALTHCARE - Drugs - Biotechnology
Generated: Thursday September 15, 2011 04:11 AM
|
|
||||||||||||||||||
Quotes About Gilead Sciences, Inc.
-
New AHF Ad Exposes Gilead On HIV Prevention Pill (BIZ)
It is distressing that PrEP is being hailed as a ‘magic HIV prevention pill' when its effectiveness is 42%, while the fact that treating people who are HIV-positive—shown to be 96% effective at reducing transmission—is being virtually ignored as a breakthrough prevention method,"
- Michael Weinstein -
AIDS Healthcare Foundation: AHF Spearheads 'Pill Bottle Protest' Over Gilead's AIDS Drug Prices
Atripla, Gilead's top selling AIDS drug, accounts for over 20% of ADAP expenditures, generating millions in revenue for the company. However, at a cost of over $10,000 per year, ADAP can no longer afford to pay for this and other Gilead drugs without price relief,"
- Eileen Garcia -
Gilead Sciences expansion in Foster City grows
To have one of the world's most renowned companies in our city, we're getting exposure,"
- Pam Frisella -
BioSpace Spotlights Northern California's Life Science Community
In 1989 BioSpace celebrated Northern California as the first major biotechnology cluster with the release of the Biotech Bay Hotbed map. Today the program features campaigns in nine Hotbed regions,"
- Mike Tansey -
AHF stages 'die-in' at Gilead headquarters
Given that Atripla is sold 'at cost' for $600 per year in developing countries, Gilead could lower the price significantly and still make a huge profit,"
- Adam Ouderkirk
No Comment
-
Gilead Sciences expansion in Foster City grows
A spokesman declined to comment other than to say, "As Gilead's business continues to grow, we are always evaluating needs to expand with regard to both laboratory and office space."
- John McCamant
Latest Company Intelligence
-
Theraclone Nabs Industry Award, Scopes Out Extra $10M Financing
Xconomy | Sep 6,'11
Seattle-based Theraclone Sciences is enjoying a moment in the national biotech spotlight today, just as it happens to be on the prowl for some new cash. Theraclone was honored today as one of the Fierce 15, an annual award that the trade publication FierceBiotech gives out to 15 emerging biotech companies around the world. In a profile of the company today by FierceBiotech editor John -
Monday Hepatitis C News Ticker; HCV Genotype 6a
HCV New Drug Research | Sep 5,'11
Bakers Union Marching Through the Labor Day Parade Image Source New On The Blog Association between lichen planus and Hepatitis C Gilead Amends Study Design for GS 9190 four-drug regimen in ongoing Hepatitis C clinical trials Hepatitis C Neuropsychiatric symptoms-“brain fog”/Study Neuropsychological alterations:The role of inflammation Telaprevir-Incivek/Boceprevir... -
Gilead Amends Study Design for GS 9190 four-drug regimen in ongoing Hepatitis C clinical trials
HCV New Drug Research | Sep 4,'11
press release Sept. 4, 2011, 11:00 a.m. EDT Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent Change Does Not Affect Ongoing "All Oral" Clinical Trials Evaluating Multiple Direct-Acting Antivirals in Combination FOSTER CITY, Calif., Sep 04, 2011 (BUSINESS -
Insiders are Trading These S&P Shares Now
TheSMSGuide Blog | Aug 27,'11
Wall St. Watchdog reveals information about recent insider trades in the constituent companies of the S&P 500. Michael J Ahearn, who is an insider at First Solar (NASDAQ:FSLR), sold 460,000 shares at a cost of $ 99.56 for a whole of $ 45,798,071 on Aug 8. He sold 133,016 shares at a cost of $ 98.62 for a whole of $ 13,117,907 on Aug 9. He sold 96,000 shares at a cost of $ 101.69 -
Gilead's HIV Drug Quad: Close But No Cigar, Yet
Seeking Alpha | Aug 22,'11
It seems investors wanted a bit more from Gilead Sciences ' ( GILD ) Quad pill. Despite hitting its primary endpoint of non-inferiority to the world's biggest-selling HIV drug Atripla , which analysts claim met prior expectations and makes Quad an approvable product, shares in the Californian company slipped 0.5% Thursday, significantly underperforming the 3-4% gains across US
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
